Journal
TRENDS IN MOLECULAR MEDICINE
Volume 12, Issue 11, Pages 537-544Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2006.09.004
Keywords
-
Funding
- NCI NIH HHS [P50 CA 89018, R01 CA 097198] Funding Source: Medline
Ask authors/readers for more resources
Gene-expression profiling has revealed several molecular subtypes of breast cancer, which differ in their pathobiology and clinical outcomes. Basal-like tumors are a newly recognized subtype of breast cancer, which express genes that are characteristic of basal epithelial cells, such as the basal cytokeratins, and are associated with poor relapse-free and overall survival. However, the genetic and epigenetic alterations that are responsible for the biologically aggressive phenotype of these estrogen receptor-negative and HER2/ErbB2-negative tumors are not well understood, thereby hindering efforts to develop targeted therapies. Here, we focus on new insights into the molecular pathogenesis of basal-like breast cancer and explore how these discoveries might impact the treatment of these poor-prognosis tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available